Search results | nps

Reports

Partnering Agreements with NPS Pharmaceuticals

The Partnering Agreements with NPS Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Insights

NPS Pharmaceuticals: Big biotech partnering trends 2009-2014

NPS Pharmaceuticals is a US based specialty company. The company mainly focuses its efforts to treat rare diseases worldwide. 

NPS Pharmaceuticals – developing and partnering for rare diseases

NPS Pharmaceuticals is a global pharmaceutical company treating rare diseases specifically focusing upon gastrointestinal and endocrine disorders.

Rumour mill has it that Shire is looking to acquire NPS Pharmaceuticals

London-listed drugmaker Shire is considering a bid for New Jersey-based NPS Pharmaceuticals, FT Alphaville reported on Friday citing sources.

NPS Pharmaceuticals: Company profile

Current Agreements Deal Analysis Update: April 2012

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in March 2012

Current Agreements Deals Update: September 2011

Welcome to the September 2011 edition of Current Agreements Deals Update

Recent developments in biotech patents

By Gareth Williams, Marks & Clark Marks & Clerk’s annual biotechnology reports have traditionally taken a sector focus, in order to provide an in-depth view of how biotech is developing technologically. This year, the report took a more strategic look at patenting activity in the biotechnology arena, and discovered a maturing approach to commercialising and more »

Events

Sorry, your search returned no results.


Deals

Shire moves to acquire NPS Pharma

Shire and NPS Pharmaceuticals have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion

Takeda biopharma partners with NPS Pharmaceutical

NPS Pharmaceuticals biopharma partners with Takeda Pharmaceutical ( a big pharma company) announcing that NPS has re-gained the full worldwide rights to teduglutide and recombinant human parathyroid hormone 1-84 (PTH 1-84) (trade name in Europe: Preotact).

Natera in private financing for $54.6 million

Natera has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera’s non-invasive prenatal test, Panorama.

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new1gif
e80banner300x150animgif
a1banner300x150animgif